lit fiuoxetine, the N-demethylated metabolite ."" uoxetine exists in R-and S-enantiomeric fonns. S-Norfluoxetine inhibited serotonin (5-HT) uptake and I'Hlptlroxetine binding to 5-HT uptake sites with a pKi of 7.86 and 8.88 or 14 and 1.3 nM, respectively, whereas l-norfluoxetine was 22 and 20 times, respectively, less pDltnt. R-and S-Norfluoxetine were less potent than the tlmSponding enantiomers of fluoxetine as inhibitors of WMpinephrine uptake and [3HJtomoxetine binding to WMpinephrine uptake sites. Ex vivo studies showed that S-norfluoxetine inhibited 5-HT uptake with an ED50 of 3 "8!kg intraperitoneally, 4.7 mglkg subcutaneously, and lEY WORDS: Fluoxetine; Norfluoxetine; Enantiomers; Strotonin 5-HT; Uptake; Inhibitors Ruoxetine, a selective inhibitor of serotonin (5-hydroxy lIyptamine, 5-HT) uptake (Wong et aI., 1974(Wong et aI., , 1975, has been successfully developed as an antidepressant drug (Feighner 1983; Beasley et al. 1990 ). Fluoxetine is de ftIoped and is marketed as the racemate, i.e., the R (-) and 5 (+) enantiomers of equal amounts. Both enantiomers inhibit 5-HT uptake and effectively pro duce functional responses associated with an increased S-HT transmission. There are no major differences in potency between R-and S-fluoxetine, and their eudis IIic ratio is close to unity (Wong et al., 1985 (Wong et al., , 1990 9 mglkg orally (7.3, 11.4 and 21.9 Jimollkg, respectively), while the ED50 for R-norfluoxetine exceeded 20 mglkg intraperitoneally (48.6 Jimollkg). Inhibition of 5-HT uptake in cerebral cortex ex vivo and decrease in 5-HIAA levels in hypothalamus persisted for 24 hours after administration of S-norfluoxetine as demonstrated with the administration of fluoxetine. Thus, S-norfluoxetine is the active N-demethylated metabolite responsible for the persistently potent and selective inhibition of 5-HT uptake in vivo. Robertson et aI. 1988). Enzymatic N-demethylation is an early step of fluoxetine metabolism, and the de methylated compound norfluoxetine (Fig. 1) is a major metabolite (Parli and Hicks 1974; Lemberger et aI. 1978; Beasley et al. 1990 ) in laboratory animals and in man. Norfluoxetine is also a potent and selective inhibitor of 5-HT uptake (Wong et aI. 1975; Horng and Wong 1976; Fuller et al. 1978) . In the present communication, we report the pharmacologic pro&les of R-and S-norfluox etine, which have been recently synthesized in high enantiomeric purity. In contrast with the two enan tiomers of fluoxetine, however, we have found that S-norfluoxetine is over 20-fold more potent than the R enantiomer as an inhibitor of 5-HT uptake both in vitro and in vivo.
9 mglkg orally (7.3, 11.4 and 21.9 Jimollkg, respectively), while the ED50 for R-norfluoxetine exceeded 20 mglkg intraperitoneally (48.6 Jimollkg). Inhibition of 5-HT uptake in cerebral cortex ex vivo and decrease in 5-HIAA levels in hypothalamus persisted for 24 hours after administration of S-norfluoxetine as demonstrated with the administration of fluoxetine. Thus, S-norfluoxetine is the active N-demethylated metabolite responsible for the persistently potent and selective inhibition of 5-HT uptake in vivo.
lNeuropsychopharmacology 8:337-344, 1993J Robertson et aI. 1988) . Enzymatic N-demethylation is an early step of fluoxetine metabolism, and the de methylated compound norfluoxetine ( Fig. 1 ) is a major metabolite (Parli and Hicks 1974; Lemberger et aI. 1978; Beasley et al. 1990 ) in laboratory animals and in man. Norfluoxetine is also a potent and selective inhibitor of 5-HT uptake (Wong et aI. 1975; Horng and Wong 1976; Fuller et al. 1978) . In the present communication, we report the pharmacologic pro&les of R-and S-norfluox etine, which have been recently synthesized in high enantiomeric purity. In contrast with the two enan tiomers of fluoxetine, however, we have found that S-norfluoxetine is over 20-fold more potent than the R enantiomer as an inhibitor of 5-HT uptake both in vitro and in vivo.
MATERIALS AND METHODS
Male Sprague-Dawley rats weighing between 100 and 150 g (Harlan Industries, Cumberland, IN) were housed in a room with a 12-hour dark/light cycle at 23°C, and Fluoxetine Norfluoxetine had free access to Purina Chow pellets and water. Rats were killed by decapitation. Brain tissues of cerebral cor tex, hypothalamus, or striatum were homogenized in 9 volumes of a medium containing 0.32 mollL sucrose and 10 mmollL glucose. Crude synaptosomal prepara tions were isolated after differential centrifugation at 1000 x g for 10 minutes and 17,000 x g for 28 minutes. The final pellets were suspended in the same medium and kept on ice until used within the same day. Synaptosomal uptake of tritium-labeled S-HT, nor epinephrine (NE), or dopamine (DA) was determined as follows: synaptosomal preparations (equivalent to O.S to 1.0 mg of protein) were incubated at 37°C for S minutes in 1 ml of Krebs bicarbonate medium contain ing also 10 mmollL glucose, 0.1 mmollL iproniazid, 1 mmollL ascorbic acid, 0.17 mmollL EDTA, and [3Hl monoamine at a specified concentration. The reaction mixture was immediately diluted with 2 ml of 0.9% sa line and filtered using Whatman GFIB filters under vacuum with a cell harvester (Brandel, Gaithersburg, MD). Filters were rinsed twice with approximately S ml of ice-chilled 0.9% saline and were transferred to a counting vial containing 10 ml of scintillation fluid (PCS; Amersham, Arlington Heights, IL.). Radioactivity was measured by a liquid scintillation spectrophotometer. Accumulation of activity at 4°C represented the back ground and was subtracted from all samples. Uptake of S-HT in human platelets was conducted according to previously described methods (Horng and Wong 1976; Lemberger et al. 1978) .
Radioligand-binding assays were conducted ac cording to previously described methods. Briefly, syn aptosomal preparations of rat cerebral cortex, bovine choroid plexus, or striatum were suspended by homog enizing in SO volumes of cold reaction medium (SO mmollL Tris-HCl, pH 7.4, with or without ISO mmollL NaCl, SO mmollL KCl) and centrifuging at SO,OOO x g for 10 minutes. The process was repeated two times NEUROPSYCHOPHARMACOLOGY 199 3 -VOL. 8, NO.1 with a 10-minute incubation at 37°C between the sec· ond and third washes. The fmal pellet was stored� -70°C until use.
Binding of [3Hlparoxetine to S-HT uptake sites WI carried out in 2 ml of reaction medium containing !hi appropriate drug concentrations, 0.1 nmollkg [3H] paroxetine and the cerebral cortical membranes (equiva lent to SO Ilg protein/tube) (Marcus son et al. 1988) , ani [3Hltomoxetine at 0.2 nmollkg was used to label NE uptake sites using a higher concentration of 300 mmott kg NaCl as previously described (Wong et al. 1991 � Samples were incubated at 37°C for 30 minutes, and those containing 1 Ilmollkg fluoxetine or desipramine were used to determine nonspecific binding of [3JIJ paroxetine and [3Hltomoxetine, respectively. Afterin cubation, the tubes were filtered through Whatman GF/B filters, which were soaked in O.OS% polyethyleni mine for 1 hour before use, using a cell harvester � adding about 4 ml of cold Tris buffer (pH 7.4), aspiri ing, and rinsing the tubes three additional times. Fillels were then placed in scintillation vials containing 10m of scintillation fluid, and the radioactivity was measured by liquid scintillation spectrophotometry. Radioligand binding assays for subtypes of receptors of 5-HT and other neurotransmitters were conducted according to previously described methods (Hoyer 1985; Wonget al. 1983 Wonget al. , 1989 Wonget al. , 1991b .
For in vivo studies, rats were fasted ovemight pria to oral administration of drugs. Groups of five rats were given drugs by specified routes and doses, and were killed by decapitation at appropriate times. Brain areas were quickly dissected and placed either in cold 0.32 mollL sucrose medium for uptake studies, or were fro. zen on dry ice for metabolite level determinations.
For measurement of S-hydroxyindoleacetic add (5-HIAA), brain tissues were homogenized in 5 to 10 volumes of 0.1 N trichloroacetic acid containing inter· nal standard (S-hydroxyindolecarboxylic acid) and C� trifuged at 10,000 x g for 10 minutes. The 5-HIAAin 20 III of supernatant was determined by high-pressure liquid chromatography and electrochemical detection.
Enantiomers Statistical analysis was conducted by the use of Stu dEnt's t-test to compare means of control and drug llated samples. A probability of less than 0.05 was re prded as signiflcant.
RESULTS
S-Norfluoxetine inhibits 5-HT uptake in synaptosomal preparations isolated from rat cerebral cortex with ilaeasing concentrations from 3 nmollkg, whereas I-norfluoxet ine exerted its inhibitory effect at much lligherconcentrations beginning at about 100 nmollkg, mdasexpected, the racemic mixture RIS-norfluoxetine had an intermediate potency ( terminations, the inhibitor constant (Ki values) were calculated from ICso values (Cheng and Prusoff 1973) and are presented as pKi ( -log Ki, M) values in Table  1 . The mean pKi for S-norfluoxetine of 7.86 ± 0.11 is signilicantly higher than the pKi values for R-norfluox etine and the racemate, indicating that the 5 enantiomer is signilicantly more potent. Contrary to these fIndings, the two enantiomers and the racemic mixture fluoxe tine inhibited 5-HT uptake with almost equipotency (Ta ble 1) as previously reported (Wong et al. 1985 (Wong et al. , 1990 .
Consistent with its potency as an inhibitor of 5-HT uptake, S-norfluoxetine was more potent than the race mate or R-norfluoxetine as an inhibitor of pHlparoxe tine binding to 5-HT uptake sites in cortical membranes (Fig. 3) . The three compounds inhibited [3Hlparoxe tine binding with mean pKi values of 8.80 ± 0.04, 8.40 ± 0.04, and 7.49 ± 0.12, respectively ( Table 2) . In agree ment with the inhibition of [3Hlfluoxetine binding ( Wong et al. 1985) , fluoxetine and its enantiomers are also potent inhibitors of [3H]paroxetine binding to 5-HT uptake carriers ( Table 2) . Uptake of 5-HT in platelets of human and rat plasma is known to be inhibited by fluoxetine and norfluoxe tine (Horng and Wong 1976) . S-Norfluoxetine inhibited 5-HT uptake in human platelets with increasing con centrations (Fig. 4) , and its ICso value was 7.5 nmollkg; S-norfluoxetine was 2 and 14 times more potent than the racemate or the R enantiomer, respectively. Like fluoxetine, norfluoxetine and its two enan tiomers were weak inhibitors of NE uptake in synap tosomal preparations (Table 1) . S-Norfluoxetine had the lowest pKi of 5.23 ± 0.04, suggesting it is the least po tent inhibitor of NE uptake among enantiomers of norfluoxetine and fluoxetine. Likewise, the two pairs of enantiomers are also weak inhibitors of OA uptake in striatal synaptosomes as previously reported for fluoxetine and norfluoxetine (Wong et al. 1990) .
Consistent with being weak inhibitors of NE up take, norfluoxetine and its enantiomers inhibited [3H]tomoxetine binding to NE uptake carriers (Wong et al. 1991a) with pKi values below 6, i.e., greater than micro molar concentrations (Table 2 ). Fluoxetine and its enantiomers were also weak inhibitors of [3H]tomox etine binding.
The abilities of R-and S-norfluoxetine to reduce 5-HT uptake ex vivo were compared (Table 3) . S-Nor fluoxetine, upon administration to rats at 3, 10, and 20 mg/kg (7.3, 24.3, and 48.6 Ilmollkg, respectively) by either intraperitoneal or subcutaneous routes, signifI cantly lowered 5-HT uptake in hypothalamus homog enates, with estimated EOso values of 3 mg/kg IP and 4.7 mg/kg Sc. R-Norfluoxetine lowered 5-HT uptake at all three doses administered, but the EOso values ex ceeded 20 mg/kg by either route of administration.
S-Norfluoxetine administered orally at 3, 10, and 20 mg/kg to rats also effectively reduced 5-HT uptake in hypothalamus homogenates with an EOso of ap proximately 9 mg/kg po an hour after its administration; the uptake of NE in the same tissue preparations remained unchanged (Table 4 ). In the same groups of rats, indole metabolites (5-HT and 5-HIAA) in cerebral cortex were measured, and 5-HT levels were essentiall y unchanged after treatment with the three doses of S-norfluoxetine; however, 5-HIAA levels were lower than control and this decrease in 5-HIAA levels became statistically signifIcant at the 20-mg/kg dose ( Table 4 ).
The duration of lowering of 5-HT uptake after a sin gle oral administration of S-norfluoxetine at 20 mg/kg was found to be comparable to that caused by a similar treatment with fluoxetine and S-fluoxetine (Wong et al. 1975 (Wong et al. , 1985 . Within an hour of treatment, 5-HT uptake in homogenates of cerebral cortex was reduced to be low 30% of control activity, and the decrease persisted for 24 hours. Levels of 5-HIAA in hypothalamus were also signifIcantly reduced at each time period of treat· Other conditions were as described in Materials and Methods. Groups of fIve rats were treated with either saline or an enantiomer of norfluoxetine at dose and route of administration indicated for an hour before killing. Hypothalamus was dissected and homogenized in 0.32 moliL sucrose. Aliquots of the homogenate in triplicate samples were incubated for uptake of 5-HT as described in Materials and Methods. SignifIcant difference from control is indi cated (* p < .001; # p < .005; t P < .05). (Table 4) , S-norfluoxetine treatment did not change s.HT levels in hypothalamus during the entire time l1IU1'Seof study (results not shown). A similar duration afdecrease of 5-HT uptake occurred following adminis traIionof S-norfluoxetine at 10 mg/kg SC, but 5-HT up take had returned to control levels by 48 hours after !Raiment (Table 5) .
Int (Figure 5). As observed in previous experiments
By means of radioligand-binding techniques, the lWoenantiomers of norfluoxetine were found to inter ICtwith receptors of transmitters only an micro molar II higher concentrations, including subtypes of 5-HT mptors (lA, lB, 10, 2, and 3); adrenergic alpha1-, �ha:z-, and beta-receptors; dopaminergic 0 1 and 0 2 mpt ors; muscarinic acetylcholine receptors; and hista mine HI receptor ( Table 6 ). Consistent with the fmdings on the enantiomers of fluoxetine (Wong et al. 1991b ), R-norfluoxetine inhibited [3H]mesulergine binding to 5-HT 1C sites in membranes of bovine choroid plexus with a Ki of 0.18 ± �mol/kg, whereas S-norfluoxetine was much weaker, with a Ki of 3.5 �mol/kg (Table 6 ).
DISCUSSION
Contrary to the equipotency of R-and S-fluoxetine as inhibitors of 5-HT uptake (Wong et al. 1985 (Wong et al. , 1990 , S-norfluoxetine is consistently more effective than R-norfluoxetine as an inhibitor of 5-HT uptake in syn aptosomal preparations and human platelets in vitro. Indeed, S-norfluoxetine exhibited 20 times greater affinity than R-norfluoxetine for the 5-HT uptake sites 3.9 ± 0.3* 4.6 ± 0.3 2.14 ± 0.05 2.24 ± 0.04 10 (24.3) 2.5 ± 0.4* 4.6 ± 0.4 2.41 ± 0.23 2.12 ± 0.06 20 (48.6) 1.7 ± 0.2* 4.6 ± 0.3 2.19 ± 0.10 1.96 ± 0.05#
Groups of fIve rats were treated with saline or S-norfluoxetine at the indicated doses and killed an hour later. Hypothalamus and cerebral cortex were dissected. Hypothalamus was homogenized in 0.32 moliL sucrose and used for measurement of 5-HT and NE uptake. Cerebral cortices were im mediately frozen for subsequent measurement of indole metabolites. Other conditions were those described in Materials and Methods.
Q Tissue weight was expressed in gram of wet weight. SignifIcant difference from control is indicated (* p < .025; # p < .002). Hours After Drug at 20 mglkg po. labeled by [3Hlparoxetine, and fluoxetine and its R and S enantiomers displaced [3Hlparoxetine binding with equal affinities, as shown previously, using [3Hlfluox etine as radio ligand binding to 5-HT uptake sites (Wong et al. 1985) . In fact, the pKi values of S-norfluoxetine are higher than the pKi value of S-fluoxetine as an in hibitor of [3Hlparoxetine binding (p < .01) in cortical preparations, suggesting that N-demethylation of S-flu oxetine appears to increase intrinsic affi nity for the 5-HT uptake carrier. Groups of four rats were treated with S-norfluoxetine at 10 mg/kg (24.3 J.lmollkg) SC and were killed at the times indicated. A group of eight rats was treated with saline as a control group. Hypothala mus was dissected and homogenized in 0.32 mollL sucrose. Aliquots of the homogenate in duplicate samples were incubated for 5-HT uptake as described under Materials and Methods. SignifIcant differ ence from control values is indicated (* p < .001).
NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.1 3.5 ± 0.5 48.5 ± 9.1 3.8 ± 0.7 >10 >10 >10 >10 >10 >10 2.8 2.5
Ki in mean ± SE were calculated from ICso values of at least tIw separate determinations. otherwise, values are shown as obtained from each determination.
Auoxetine and norfluoxetine, as reported previ ously (Wong et al. 1975 (Wong et al. , 1990 , and their respective enantiomers as demonstrated in the present study, are weak inhibitors of NE uptake. Using [3Hltomoxetine as a radioligand of NE uptake carrier (Wong et al. 1991a ) , we further show that norfluoxetine and its enantiomers are indeed weaker ligands for the NE uptake carri er. Calculating the ratios of Ki inhibiting [3Hltomoxe tine binding to Ki inhibiting [3Hlparoxetine binding, the values for fluoxetine, R-fluoxetine, S-fluoxetine, norfluoxetine, R-norfluoxetine, and S-norfluoxetine (Table 2) are 33, 20, 219, 697, 58, and 1317, respectively. In agreement with the inhibition of 5-HT and NE up' take, inhibition of direct radioligand binding to the respective uptake sites shows a minimum of 20-fold greater affinity of R-fluoxetine for 5-HT than for NE up' take sites, whereas the selectivity of S-fluoxetine was 21 times higher, with a ratio of 219. Unexpectedly, N-demethylation of S-fluoxetine to S-norfluoxetine con fers an even greater selectivity for the 5-HT uptake sites over NE uptake sites, with a Ki ratio of 1317. Even though R-norfluoxetine has one-eighth the affini ty m R-fluoxetine for the [3Hlparoxetine-Iabeled 5-HT up' take site, it also has one-third the affinity of the parent drug for the [3Hltomoxetine-Iabeled NE uptake.
The present study demonstrates that S-norfluoxe tine is as potent as S-fluoxetine in inhibiting 5-HT up' take ex vivo (Wong et al. 1985) . The dosed EDso values of S-norfluoxetine ranged from 3 to 9 mg/kg afte r in traperitoneal, subcutaneous, and oral routes of adminis tration, suggesting excellent bioavailability and ready penetration into the brain. Consistent with the in vitro ftndings, R-norfluoxetine was relatively inactive as a 5-HT uptake inhibitor ex vivo with EDso doses exceed ing 20 mg/kg. In vivo, fluoxetine and norfluoxetine at !lmg/kg!P, more than twice the ED50 inhibiting 5-HT aptake ex vivo, failed to inhibit the accumulation of ra dioactive NE in rat heart, whereas the tricyclic anti depressant drugs imipramine, desipramine, clomipra mine, and chlorodesipramine at 5 mg/kg IP nearly maximally inhibited accumulation of NE radioactivity it heart (Wong et al. 1975) .
The duration of 5-HT uptake inhibition was longer Iter an administration of S-fluoxetine than R-fluoxe line (Wong et al. 1985) . Both enantiomers are readily metabolized to form norfluoxetine (Potts et al. 1989; Full eret aI. 1991; Potts and Parli 1992) . The loss of in lii tory effects beginning 5 hours after R-fluoxetine ad ministration can be explained by the generation of a rel llively inactive metabolite, R-norfluoxetine, since both I· or S-norfluoxetine reached similar peak levels in brain between 4 and 8 hours after administration of the cor ISpOnding enantiomer of fluoxetine (Fuller et al. 1990 ).
On the other hand, the N-demethylation of S-fluoxe tile leads to an equally active and enduring metabo iIf, S-norfluoxetine, which was responsible for the bIg·lasting inhibition of 5-HT uptake after treatment with S-fluoxetine (Wong et al. 1985) .
The Ki ratios of S-fluoxetine (219) and S-norfluox tIine (1317) are 11 and 22 times higher than the Ki rams of R-fluoxetine (20 and R-norfluoxetine (58), IIftSfnting a broad range of selectivity for the uptake aniers of 5-HT over those of NE. Despite having a low llectivity ratio of 20 and the submicromolar affinity of '-6uoxetine for NE uptake sites, administration of ra Clll lic fluoxetine to rats in vivo at doses up to 13 times 6r EDso (3. 8 mg/kg i. p.) for inhibition of 5-HT in vivo flied to inhibit NE uptake in brain and in heart (Wong ltal.1975; Wong and Bymaster 1976) . Higher doses 1m rarely used and would be considered unneces II}'. Since the enantiomers of the parent drug and the Bethylated metabolite should bear comparable phys aI and chemical properties, their tissue distribution imost likely to be similar. Comparable brain levels of 6renantiomers of fluoxetine and norfluoxetine were ideed achievable after a single dose of racemic fluoxe .in rat (Potts and Parli 1992) . Thus, a 5-HT uptake ihibitor, having a selectivity ratio of 20 like R-fluoxe a,appears to provide adequate selectivity in vivo to mlinhibiting 5-HT uptake without inhibiting NE up tie. In a recent clinical study, four individuals receiving mmic fl uoxetine daily for 45 days showed nearly a blrfol d higher rate of clearance for R-fluoxetine com pftd to S·fluoxetine (R. Bergstrom, personal commu Don). As a result, one can expect that S-fluoxetine ll1IlII ulates to higher concentrations than R-fluoxetine .consequently ensures selectivity toward inhibiting SHr uptake in humans.
Besides fluoxetine and the tertiary amine contain .. tricyclic antidepressant drugs, including imipramine IIddomipramine (Wong et al. 1975 , Hyttel and Lar-R-and S-Norfluoxetine, Inhibitors of 5-HT Uptake 343 sen 1985), N-demethylation is also involved in the me tabolism of other selective inhibitors of 5-HT uptake. Sertraline, a secondary amine, inhibited 50% of 5-HT uptake with a concentration of 58 nmol/kg (ICso) and NE uptake with an ICso of 1200 nmol/kg, whereas the N-demethylated metabolite, CP 62,508, inhibited 5-HT and NE uptake with ICsos of 450 and 4600 nmol/kg, respectively (Koe et al. 1983) . Thus, the ratio of ICso in hibiting NE uptake to the ICso inhibiting 5-HT uptake was reduced from 20 for sertraline to 10 for the des methyl metabolite of sertraline. In ex vivo studies, ser traline was shown to be a selective inhibitor of 5-HT uptake without signifIcant inhibition of NE uptake (Koe et al. 1983) .
Citalopram, a tertiary amine, and its N-demethyl ated metabolites desmethylcitalopram and dides methylcitalopram inhibited 5-HT uptake with IC50S of 1.8, 7.4 and 24 nmol/kg, respectively, and were 4889, 105, and 63 times, respectively, less potent as inhibi tors of NE uptake (Hyttel and Larsen, 1985) . At twice the ED50 dose inhibiting 5-HT uptake ex vivo, citalopram at 10 mg/kg IP did not reduce NE uptake in midbrain synaptosomes of drug-treated rats (Maitre et al. 1980) . Like other inhibitors of 5-HT uptake, including fluoxetine, oral administration of S-norfluoxetine at 20 mg/kg caused a decrease of 5-HIAA levels in hypothala mus and cerebral cortex, whereas 5-HT levels in these brain areas were essentially unchanged. It is believed that the decrease in 5-HIAA levels reflects a decrease of 5-HT turnover, a consequence of greater synaptic availability of 5-HT when presynaptic 5-HT uptake is inhibited.
The two enantiomers of norfluoxetine are similar to fluoxetine (Wong et al. 1983 ) and its two enantiomers (Wong et al. 1985) , and have little affinity for receptors of neurotransmitters, including 5-HT, NE, DA, acetyl choline, and histamine. The relatively low affinity of the norfluoxetine enantiomers for receptors of acetyl choline (muscarinic class) and histamine is consistent with the low incidence of anticholinergic and anti histaminergic side-effect profIles of fluoxetine and norfluoxetine (Feighner 1983; Beasley et al. 1990 ). Among subtypes of 5-HT receptors, R enantiomers of norfluoxetine (present study) and fluoxetine (Wong et al. 1991 ) exhibit submicromolar affinity for 5-HTlC receptors in membranes of bovine choroid plexus; how ever, it should be noted that the affinity of the two R enantiomers for the 5-HT uptake site is two orders of magnitude higher. Nevertheless, the pharmacologic effects of the two R enantiomers on 5-HTlC receptors are an important area for further investigation.
ACKNOWLEDGMENT
We thank Mrs. Joan Hager for preparation of the manuscript.
